Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

How much should investors expect sales of Keytruda, the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.